Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


France Proposes Mediator Injury Compensation Program, Pressuring Servier To Fund It

This article was originally published in The Pink Sheet Daily

Executive Summary

Proposal would also shield French regulatory agency that approved the diabetes drug from victims' lawsuits.

You may also be interested in...

NICE Backing For Procolaran In CHF May Prove Lucrative For Servier

If NICE’s backing for Servier’s heart drug Procolaran does spread across Europe, then the resulting returns may offset some of financial pain the French group is set to feel in coming years.

EU Pharmacovigilance Fees Could Cripple Drug Firms, Says Pharma Industry

Fees set to be introduced to cover the cost of the European Medicines Agency’s part in improving drug safety could impose a huge burden on the EU pharmaceutical industry and lead to the closure of smaller firms, the industry says.

Servier’s EU Nightmare Continues As Commission Moves To Shut Down Disputed IP Practices

The European Commission’s allegations against Servier for alleged patent abuses could help to clarify the law in this area for original product manufacturers in the long term.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts